FeesSafety
Pluang+

Immuron posts 9% global sales growth in Q1, led by strong Travelan® gains in Australia and Canada.

Company Fundamentals
27 Oct 2026, 13:00 WIB
GlobeNewsWire
View Source
Bullish
Immuron posts 9% global sales growth in Q1, led by strong Travelan® gains in Australia and Canada.

Immuron Limited reported a 9% increase in global sales to AUD$2.2 million for Q1 ending September 30, 2026, driven by a 14% rise in Australian sales and a 286% surge in Canadian sales of its Travelan® product. The Australian growth is attributed to a successful Travelan® brand relaunch, while Canadian sales benefited from increased brand awareness and product sampling. U.S. sales declined due to inventory challenges but are expected to improve with upcoming promotional events. Immuron continues to expand its product portfolio with offerings like PROIBS® and IMM-529, targeting digestive health and infectious diseases.

Immuron's quarterly sales growth is presented here with Pluang's Health sector market data as of Oct 27, 2026 16:11 WIB. Among 150 priced Health-sector US stocks tradable on Pluang, 61 rose and 75 fell today. Notable movers include MRVI at USD 7.22 with a -4.75% change, BNGO at USD 1.12 with a -3.45% change and 100% sell order activity, and CRON at USD 3.41 with a +3.02% change.

More News

CareCloud appoints Mitchell Brie as Chief Compliance Officer to boost its healthcare compliance services.

CareCloud appoints Mitchell Brie as Chief Compliance Officer to boost its healthcare compliance services.

CareCloud has named Mitchell Brie as Chief Compliance Officer to lead its growing healthcare compliance business. Brie, founder of Empower Healthcare & Compliance Partners (acquired by CareCloud), will oversee corporate compliance and continue as Pre...

Market News
Bullish
44 minutes ago
Defense contractors must review CUI access before licensing Microsoft 365 Copilot in GCC High cloud.

Defense contractors must review CUI access before licensing Microsoft 365 Copilot in GCC High cloud.

eSoftware Associates advises defense contractors to carefully map controlled unclassified information (CUI) access permissions before licensing Microsoft 365 Copilot in the GCC High cloud environment. Moving to GCC High does not automatically grant c...

Market News
Neutral
1 hour ago
Man Group discloses 5.64% stake in Vesuvius plc amid offer involving RHI Magnestia N.V.

Man Group discloses 5.64% stake in Vesuvius plc amid offer involving RHI Magnestia N.V.

Man Group PLC has publicly disclosed holding a 5.64% interest in Vesuvius plc, including direct shares and cash-settled derivatives. This disclosure is related to an ongoing offer involving RHI Magnestia N.V., which is also named in the filing. The d...

Neutral
1 hour ago
Nautilus reports Q3 2026 results with $0.2M revenue, $15.6M net loss, and advances in proteome analysis tech.

Nautilus reports Q3 2026 results with $0.2M revenue, $15.6M net loss, and advances in proteome analysis tech.

Nautilus Biotechnology announced its Q3 2026 financial results, reporting $0.2 million in revenue mainly from grants and early access services, and a net loss of $15.6 million. The company highlighted progress in its proteome analysis platform, inclu...

Company Fundamentals
Bullish
2 hours ago
Eviden launches ASTRA-LAS, a new AI-powered tactical decision-support tool for naval operations.

Eviden launches ASTRA-LAS, a new AI-powered tactical decision-support tool for naval operations.

Eviden, part of Atos Group, has introduced ASTRA-LAS, a tactical decision-support solution designed to aid naval officers in complex maritime environments. The system uses operational data and AI to enhance situational awareness, reduce cognitive loa...

Others
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App